BioSpace News Archive

BioMidwest

Heartland Dental Hosts Supported Dentists and Dental Assistants for First-Annual Implant Continuum

The Company helps supported dental professionals advance their skills in dental implants

December 3, 2018
·
2 min read
Pharm Country

Henry Schein Disaster Relief Hotline Is Open To Support Customers Affected By Earthquake In Alaska

Dentists, Physicians, and Veterinarians Who May Experience Operational, Logistical, or Financial Issues Encouraged to Call 800-999-9729

December 3, 2018
·
3 min read
Drug Development

Ascentage Pharma Announces Oral Presentation of Novel, Third-Generation BCR-ABL Inhibitor in Myelogenous Leukemia Patients at the 60th American Society of Hematology Annual Meeting

Ascentage Pharma today announced data from a Phase 1 clinical study of its novel BCR-ABL inhibitor, HQP1351, in patients with Tyrosine Kinase Inhibitor (TKI)-refractory chronic myelogenous leukemia (CML) at the 60th American Society of Hematology (ASH) Annual Meeting.

December 3, 2018
·
3 min read
Biotech Beach

When Good Macrophages Go Bad: New Study Reveals How Cancer Manipulates Our Immune System to Become Harder to Treat

Many factors affect cancer treatment outcome, such as the size and location of the tumor, availability of effective treatments, and timing of intervention.

December 3, 2018
·
4 min read
Biotech Bay

GRAIL Announces Plans to Initiate SUMMIT Study to Support Development of Blood Test for Early Cancer Detection

SUMMIT Study Partners Include UCL and University College London Hospitals NHS Foundation Trust in the United Kingdom, and Lung Cancer Alliance

December 3, 2018
·
5 min read
Drug Development

Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018

Phase 1 Results of Amgen’s BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid Leukemia

December 3, 2018
·
13 min read
Drug Development

bluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology

LentiGlobin treatment-derived hemoglobin HbAT87Q equals or exceeds sickling hemoglobin (HbS) levels in Group C patients at six months post treatment

December 3, 2018
·
8 min read
Drug Development

bluebird bio Presents New Data for LentiGlobin Gene Therapy in Transfusion Dependent β-Thalassemia at 60th Annual Meeting of the American Society of Hematology

First presentation of data from patients with a β0/β0 genotype and a pediatric patient treated with LentiGlobin in Phase 3 Northstar-3 study both have stopped chronic blood transfusions

December 3, 2018
·
9 min read
Drug Development

Aruvant Sciences Presents Data from Ongoing Clinical Study of Lentiviral Gene Therapy RVT-1801 for Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology

Two patients have been administered RVT-1801 in conjunction with reduced intensity conditioning regimens

December 3, 2018
·
5 min read